A Safety Study in Patients With Chronic Lymphocytic Leukemia

NCT ID: NCT00283101

Last Updated: 2014-12-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-07-31
• Study Completion Date: 2006-10-31

Brief Summary

This is an open-label, dose-escalation study to determine the tolerability, safety profile, and antitumor activity of SGN-40 in patients with CLL. All patients will receive dose escalation during the first two weeks regardless of cohort designation.

Detailed Description

A minimum of three patients will be entered into each dose-level cohort for five weeks. Escalation to the next cohort will occur when three patients have received at least one infusion at the highest scheduled dose level, and at least one patient has completed the entire five week dosing schedule. Cohorts will be enrolled at a maximal dose level of 3, 4, 6, or 8 mg/kg/week. Initial therapy will last for 5 weeks. Responding patients will receive additional infusions every two weeks x 4 at the maximal dose for each specific cohort.

Conditions

Leukemia, Lymphocytic, Chronic

Keywords

Antigens, CD40; Antibody, Monoclonal; Leukemia, Lymphocytic, Chronic, B-Cell; Hematologic Diseases; Immunoproliferatic Disorders; Lymphatic Diseases; Lymphoproliferative Disorders; Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

SGN-40

Group Type: EXPERIMENTAL

SGN-40 (anti-huCD40 mAb)

Intervention Type: DRUG

1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.

Interventions

SGN-40 (anti-huCD40 mAb)

1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.

Intervention Type: DRUG

Other Intervention Names

dacetuzumab

Eligibility Criteria

Inclusion Criteria

1. Patients must have a histologic diagnosis of CLL as defined by the WHO criteria and exhibit active disease requiring treatment as per the NCI working group on CLL.

2. Patients must have a fresh tumor specimen available (peripheral blood or bone marrow) for flow cytometry evaluation (e.g. CD40, CD38, CD20, CD19, and CD5).For the phase 2 portion of the study, CD40 expression on malignant cells must be confirmed prior to registration.

3. Patients must have relapsed after receiving at least one fludarabine containing regimen or an equivalent purine analog.

At study start patients must be at least 8 weeks or 5 plasma half-lives (whichever is greater) from prior chemotherapy/radiation/investigational agents, 8 weeks from prior antibody therapy and 6 months from autologous stem cell transplant.

4. Patients must have an ECOG performance status ≤ 2 and a life expectancy > 3 months.

5. Patients must have the following required baseline laboratory data:

• Platelet count ≥ 50,000/mm3 (may be maintained by transfusion)
• Hemoglobin ≥ 7.5 g/dL (may be maintained by transfusions or growth factors)
• Absolute neutrophil count ≥ 1,000/mm3 (may be maintained by growth factors)
• ALT/AST ≤ 2.0 times ULN
• Total bilirubin ≤ 2.0 times ULN (unless related to hemolysis)
• Creatinine < 2.0 times ULN

6. Females of childbearing potential must have a negative B-hCG pregnancy test result within 3 days prior to the first dose and must agree to use an effective contraceptive method during the course of the study and for 6 months following the last dose of study drug.

7. If a deep venous thrombosis or other vascular event has required medical or surgical intervention in the past year, patients must either: a) be on a stable dose of anticoagulant therapy (i.e., Coumadin and/or Heparin) for at least three weeks or b) have completed anticoagulant therapy at least three months prior to registration with radiographic confirmation that thrombosis is resolved. Prophylactic anticoagulant therapy for indwelling catheters is acceptable.

8. Patients must be at least 18 years of age.

9. Patients must be available for periodic blood sampling, study-related assessments, and management of toxicity at the treating institution.

10. Patients must give written informed consent. A copy of the signed informed consent form will be retained by the treating institution.

Exclusion Criteria

1. Patients who have been treated previously with any anti-CD40 antibody.

2. Patients with a documented history within 6 months of registration of a cerebral vascular event (stroke or TIA), unstable angina, or myocardial infarction.

3. Patients with active CNS or leptomeningeal disease.

4. Patients who have received allogeneic stem cell transplant.

5. Patients who have had major surgery within four weeks prior to enrollment.

6. Patients with a known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation.

7. Patients with a history of another primary malignancy that has not been in remission for at least 5 years (non-melanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear are exempt from the five year limit).

8. Patients with any systemic viral, bacterial, or fungal infection that has required antibiotic therapy within four weeks prior to enrollment. Prophylactic antibiotics and antiviral therapy are permitted prior to registration and are required during the study period (e.g. Bactrim, acyclovir).

9. Patients with known HIV, hepatitis B (by surface antigen expression), or active hepatitis C infection.

10. Patients on systemic steroids who have not been on a stable daily dose during the four weeks immediately prior to first dose of SGN-40. Maximum steroid dose is 10 mg prednisone per day or equivalent.

11. Patients with a history of migraines or severe headaches requiring medical therapy (other than occasional acetaminophen, aspirin, or non-steroidal anti-inflammatory drugs) within 12 months of enrollment.

12. Patients who are pregnant or breastfeeding.

13. Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment.

14. Patients with dementia or altered mental status that would preclude the understanding and/or rendering of informed consent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: collaborator

Seagen Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Seattle Genetics

Principal Investigators

Jonathan Drachman, MD

Role: STUDY_DIRECTOR

Seagen Inc.

Locations

University of Alabama at Birmingham

Birmingham, Alabama, United States

University of Miami, Sylvester Comprehensive Cancer Center

Miami, Florida, United States

Weill Medical College/Cornell University

New York, New York, United States

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Countries

United States

References

Furman RR, Forero-Torres A, Shustov A, Drachman JG. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Feb;51(2):228-35. doi: 10.3109/10428190903440946.

Reference Type: RESULT

PMID: 20038235 (View on PubMed)

Related Links

http://www.ncbi.nlm.nih.gov/pubmed/20038235

Related Info

Other Identifiers

SG040-0003

Identifier Type: -

Identifier Source: org_study_id